Medline Inc. Class A Common Stock
Medline Inc. manufactures med-surg products serving the hospital, surgery centers, physician offices, post-acute facilities, and nursing home sites of care in the United States and Internationally. It operates through two segments: Medline Brand and Supply Chain Solutions. The Medline Brand segment procures and manufactures products from three product categories include surgical solutions, front … Read more
Medline Inc. Class A Common Stock (MDLN) - Net Assets
Latest net assets as of September 2025: $17.14 Billion USD
Based on the latest financial reports, Medline Inc. Class A Common Stock (MDLN) has net assets worth $17.14 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($36.88 Billion) and total liabilities ($19.74 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $17.14 Billion |
| % of Total Assets | 46.47% |
| Annual Growth Rate | -2.66% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Medline Inc. Class A Common Stock - Net Assets Trend (2023–2024)
This chart illustrates how Medline Inc. Class A Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medline Inc. Class A Common Stock (2023–2024)
The table below shows the annual net assets of Medline Inc. Class A Common Stock from 2023 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $16.52 Billion | -2.67% |
| 2023-12-31 | $16.98 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medline Inc. Class A Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 0.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $16.15 Billion | 97.72% |
| Other Comprehensive Income | $11.00 Million | 0.07% |
| Other Components | $366.00 Million | 2.21% |
| Total Equity | $16.52 Billion | 100.00% |
Medline Inc. Class A Common Stock Competitors by Market Cap
The table below lists competitors of Medline Inc. Class A Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bank Rakyat
PINK:BKRKY
|
$33.93 Billion |
|
Nutrien Ltd
NYSE:NTR
|
$34.02 Billion |
|
Kimberly-Clark Corporation
NYSE:KMB
|
$34.04 Billion |
|
Intact Financial Corporation
PINK:IFCZF
|
$34.07 Billion |
|
Orix Corp Ads
NYSE:IX
|
$33.82 Billion |
|
ResMed Inc
NYSE:RMD
|
$33.81 Billion |
|
Alcon Inc.
XETRA:2U3
|
$33.73 Billion |
|
Orange SA
XETRA:FTE
|
$33.65 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medline Inc. Class A Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 16,977,000,000 to 16,524,000,000, a change of -453,000,000 (-2.7%).
- Net income of 1,200,000,000 contributed positively to equity growth.
- Share repurchases of 20,000,000 reduced equity.
- Other comprehensive income decreased equity by 177,000,000.
- Other factors decreased equity by 1,456,000,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.20 Billion | +7.26% |
| Share Repurchases | $20.00 Million | -0.12% |
| Other Comprehensive Income | $-177.00 Million | -1.07% |
| Other Changes | $-1.46 Billion | -8.81% |
| Total Change | $- | -2.67% |
Book Value vs Market Value Analysis
This analysis compares Medline Inc. Class A Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.01x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $21.57 | $42.16 | x |
| 2024-12-31 | $20.99 | $42.16 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medline Inc. Class A Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.26%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.70%
- • Asset Turnover: 0.71x
- • Equity Multiplier: 2.18x
- Recent ROE (7.26%) is above the historical average (4.32%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 1.38% | 1.01% | 0.64x | 2.13x | $-1.46 Billion |
| 2024 | 7.26% | 4.70% | 0.71x | 2.18x | $-452.40 Million |
Industry Comparison
This section compares Medline Inc. Class A Common Stock's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medline Inc. Class A Common Stock (MDLN) | $17.14 Billion | 1.38% | 1.15x | $33.89 Billion |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |